Today, 12:47 PM
Today, 9:18 AM
Yesterday, 5:43 PM
Yesterday, 4:21 PM
- Bluebird bio (NASDAQ:BLUE) and Five Prime Therapeutics (NASDAQ:FPRX) enter into a collaboration to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies based on Five Prime's proprietary human antibodies to a undisclosed cancer target for hematologic malignancies and solid tumors.
- Under the terms of the agreement, bluebird will have exclusive rights to Five Prime's novel human antibodies to the target and will develop CAR-T therapies against the target using its proprietary lentiviral gene therapy platform and CAR-T expertise. Five Prime will receive a $1.5M upfront payment, milestones up to ~$128.5M and tiered royalties on commercial sales. Bluebird will conduct and fund clinical trials as well as regulatory and commercial activities.
Fri, May 15, 11:46 AM
- Five Prime Therapeutics (FPRX -0.7%) initiated with Outperform rating and $45 (114% upside) price target by Oppenheimer.
- Trillium Therapeutics (TRIL +9%) initiated with Outperform rating and $32 (60% upside) price target by Oppenheimer.
- Paratek Pharmaceuticals (PRTK +1.5%) initiated with Outperform rating and $43 (54% upside) price target by Leerink Swann and a Buy rating with $35 (25% upside) price target by Cantor Fitzgerald.
- Advaxis (ADXS +2.2%) initiated with Buy rating and $26 (37% upside) price target by Janney Capital.
- SAGE Therapeutics (SAGE +1.1%) initiated with Buy rating and $80 (36% upside) price target by Goldman Sachs.
- Bristol-Myers Squibb (BMY) initiated with Hold rating and $70 (3% upside) price target by Berenberg.
- Akebia Therapeutics (AKBA +2.3%) initiated with Buy rating and $18 (125% upside) price target by Brean Capital.
- Merrimack Pharmaceuticals (MACK +1.8%) initiated with Buy rating and $15 (20% upside) price target by Guggenheim Securities.
- Tokai Pharmaceuticals (TKAI +0.4%) initiated with Outperform rating and $38 (217% upside) price target by Oppenheimer.
Wed, May 13, 4:19 PM| Comment!
Tue, May 12, 5:35 PM
Thu, Apr. 2, 5:38 PM
Tue, Mar. 31, 12:37 PM
- Former Nomura analyst Amit Roy says the market for cancer immunotherapies called PD-1 inhibitors will only be ~$10B, far below the $20B - 30B forecasts being circulated today. He cites two main factors that could hamper growth: they only work for certain groups of cancer patients plus several layers of selection will be required for some cancers such as breast and colorectal, and there is a growing evidence that shorter therapy, cutting the treatment period to eight from 16 weeks, may be sufficient. If this comes to fruition, it would shrink the market by almost half (although a price increase could mitigate some of the shrinkage).
- PD-1 (programmed cell death protein 1) is found on the surface of cancer cells. It is used by tumors to evade the immune system so blocking its action enables the body to attack and kill cancer.
- Current FDA-approved PD-1 inhibitors are Bristol-Myers Squibb's (BMY -1.2%) Opdivo (nivolumab) and Merck's (MRK -0.7%) Keytruda (pembrolizumab).
- PD-1-related tickers: (MDVN -2.4%)(FPRX -1.2%)(CELG -3.1%)(OTCQX:RHHBY +0.6%)(AZN -1.7%)(SRNE +3.4%)
Wed, Mar. 18, 9:08 AM
- Five Prime Therapeutics (FPRX +3.3%) Q4 results: Revenues: $4.6M (+21.1%); R&D Expense: $12.6M (+55.6%); SG&A: $4M (+33.3%); Operating Loss: ($11.9M) (-63.0%); Net Loss: ($11.8M) (-61.6%); Loss Per Share: ($0.55) (-27.9%).
- FY2014 results: Revenues: $19.2M (+39.1%); R&D Expense: $43.2M (+31.7%); SG&A: $13.6M (+30.8%); Operating Loss: ($37.6M) (-27.9%); Net Loss: ($37.4M) (-29.4%); Loss Per Share: ($1.79) (+65.8%); Quick Assets: $149.1M (+97.0%).
- 2015 Guidance: Cash burn: less than $65M; Quick assets: more than $160M.
Tue, Mar. 17, 5:38 PM
Tue, Mar. 17, 4:07 PM| Comment!
Sun, Jan. 11, 10:29 PM
- Based on an assessment by the independent Data Monitoring Committee, Bristol-Myers Squibb (NYSE:BMY) stops its Phase 3 trial, CheckMate-017, evaluating Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced squamous cell non-small cell lung cancer (NSCLC). The committee concluded that the study met its primary endpoint of demonstrating superior overall survival (OS) compared to docetaxel. This is the first time a PD-1 inhibitor has shown a survival advantage in lung cancer.
- Eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension.
- The company will complete a full analysis of the data and work with investigators on the future presentation and publication of the results.
- PD-1-related tickers: (NASDAQ:MDVN) (NYSE:MRK) (NASDAQ:FPRX) (NASDAQ:CELG) (OTCQX:RHHBY) (NYSE:AZN)
Tue, Jan. 6, 8:22 PM
Mon, Jan. 5, 4:39 PM
- Five Prime Therapeutics (NASDAQ:FPRX) plans to offer $75M in common stock for public sale pursuant to a shelf registration. Underwriters over-allotment is an additional 15%.
- Proceeds will fund the advancement of FPA008, FPA144, additional research and preclinical development activities and general corporate purposes.
Dec. 15, 2014, 12:36 PM
- Added to the Nasdaq Biotechnology Index, effective Dec. 22: AAVL, AERI, AKBA, ALDR, ALIM, AMPH, ANIP, ASPX, CARA, CGEN, CLDN, CNCE, ENTA, FLML, FMI, FOLD, FPRX, GWPH, HPTX, ICPT, INO, INSM, KITE, KPTI, MGNX, OPHT, PCYC, PETX, POZN, PTX, QLTI, RARE, RCPT, RDUS, RLYP, RTRX, RVNC, SAGE, TBPH, TTPH, VSAR, XLRN, ZFGN, ZSPH.
- Deleted: AMRN, AUXL, CRIS, EXPR, ICEL, ONTX, RIGL, ZGNX.
- Source: Press Release
FPRX vs. ETF Alternatives
Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering & developing novel protein therapeutics to improve lives of patients with serious diseases. Its product include FP-1039/GSK3052230, FPA008 & FPA144.
Other News & PR